TheraRadar
← Back
Data updated: Mar 29, 2026

AMPHASTAR PHARM

OncologyInfectious DiseaseRespiratory
Pharma

AMPHASTAR PHARM is a pharmaceutical company focused on Oncology, Infectious Disease, Respiratory.

2004
Since
3
Drugs
-
Trials
56
Approved (2yr)

Key Drugs

No active drugs

Top Drug Revenues Pro

Loading...

Revenue Over Time Pro

Loading...

Recent Activity

KETOROLAC TROMETHAMINE 2026-01-22
Labeling
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2026-01-07
ENOXAPARIN SODIUM (PRESERVATIVE FREE) 2025-11-25
Labeling
KETOROLAC TROMETHAMINE 2024-11-21
Labeling
KETOROLAC TROMETHAMINE 2024-11-21
Labeling
KETOROLAC TROMETHAMINE 2024-11-21
Labeling
KETOROLAC TROMETHAMINE 2024-11-21
Labeling
KETOROLAC TROMETHAMINE 2024-11-21
Labeling
SEC Filings Pro
Loading...

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Oncology 35%
0 drugs Phase 3: 3 Phase 1: 2
Infectious Disease 20%
0 drugs Phase 3: 1 Phase 2: 2
Respiratory 18%
1 drugs Phase 1: 1
Cardiovascular 15%
1 drugs
Dermatology 13%
0 drugs Phase 3: 1 Phase 1: 1

Pipeline Forecast

Loading...

Upcoming Trial Milestones Pro

Loading...

Patent Cliff Pro

Loading...

Competitors by Therapeutic Area

Baxter specialty
Infectious Disease, Cardiovascular, Oncology, Dermatology
Pfizer big-pharma
Oncology, Infectious Disease, Dermatology
COSETTE other
Cardiovascular, Dermatology, Infectious Disease, Oncology
Novartis big-pharma
Oncology, Cardiovascular, Respiratory
GE HEALTHCARE specialty
Infectious Disease, Cardiovascular, Oncology, Respiratory